VIVID-2 (I6T-MC-AMAX)
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
- Sex at Birth: Any
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Colon, Small Intestine, Crohns Disease
Study Purpose
This is a follow up study for those that participated in an originator adult mirikizumab CD study. The purpose of this study is to determine whether mirikizumab (LY3074828) can help patients with Crohn’s disease when taken for a longer time and how safe mirikizumab is and whether you might have any side effects when you take it for a long time.
Locations
UH Minoff Health Center at Chagrin Highlands
3909 Orange Place
Orange Village OH, 44122
UH Ahuja Medical Center
3999 Richmond Road
Beachwood OH, 44122
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001181
- StudyID: 2020-0142
- ClinicalTrials.gov: NCT02105849
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422